Antibodies against recombinant human alpha-glucosidase do not seem to affect clinical outcome in childhood onset Pompe disease

Harmke A. van Kooten1, Imke A. M. Ditters2, Marianne Hoogeveen-Westerveld3, Edwin H. Jacobs3, Johanna M. P. van den Hout2, Pieter A. van Doorn1, W. W. M. Pim Pijnappel3, Ans T. van der Ploeg2 and Nadine A. M. E. van der Beek1,4*

Abstract

Background: Enzyme replacement therapy (ERT) with recombinant human alpha-glucosidase (rhGAA, alglucosidase alfa) has improved survival, motor outcomes, daily life activity and quality of life in Pompe patients. However, ERT in Pompe disease often induces formation of antibodies, which may reduce the efficacy of treatment and can lead to adverse events. In this study antibody formation and their effect on clinical outcome in patients with childhood onset Pompe disease treated with enzyme replacement therapy (ERT) with recombinant human alpha-glucosidase (rhGAA) are analyzed.

Methods: Enzyme-linked immunosorbent assay (ELISA) was used to determine anti-rhGAA antibody titers at predefined time points. The effect of antibodies on rhGAA activity (neutralizing effects) was measured in vitro. Clinical effects were evaluated by assessing muscle strength (MRC score) and function (QMFT-score), pulmonary function and infusion associated reactions (IARs).

Results: Twenty-two patients were included (age at start ERT 1.1–16.4 years, median treatment duration 12.4 years). Peak antibody titers were low (< 1:1250) in 9%, intermediate (1:1250–1:31,250) in 68% and high (≥ 1:31250) in 23% of patients; three patients (14%) had more than one titer of ≥ 1:31,250. Four patients (18%) experienced IARs; two patients from the high titer group had 86% of all IARs. Inhibition of intracellular GAA activity (58%) in vitro was found in one sample. The clinical course did not appear to be influenced by antibody titers.

Conclusions: Ninety-one percent of childhood onset Pompe patients developed anti-rhGAA antibodies (above background level), a minority of whom had high antibody titers at repeated time points, which do not seem to interfere with clinical outcome. High antibody titers may be associated with the occurrence of IARs. Although the majority of patients does not develop high titers; antibody titers should be determined in case of clinical deterioration.

Keywords: Antibodies, Enzyme replacement therapy, Pompe disease, Recombinant human alpha-glucosidase

Background

Pompe disease (glycogen storage disease type II or acid maltase deficiency, OMIM #232300) is a rare inherited metabolic and neuromuscular disorder, caused by disease-associated variants in the GAA gene, leading to deficiency of the lysosomal enzyme acid α-glucosidase [1]. In patients with the classic infantile form, a complete
lack of α-glucosidase activity causes a rapidly progressive disease, characterized by a hypertrophic cardiomyopathy and severe skeletal and respiratory muscle weakness. Untreated, these infants die within the first year of life [2]. In ‘late-onset’ or ‘non-classic’ Pompe disease, which can present at any age, progressive limb-girdle and respiratory muscle weakness are the main symptoms [3, 4].

Enzyme replacement therapy (ERT) with recombinant human alpha-glucosidase (rhGAA, alglucosidase alfa, Myozyme®) received market authorization in 2006 and has improved survival, motor outcomes, daily life activity and quality of life in Pompe patients [5–10]. However, similar to any other disease treated with human recombinant proteins, ERT in Pompe disease often induces formation of antibodies, which may reduce the efficacy of treatment and can lead to adverse events [11]. Risk factors for the development of high antibody titers in classic infantile Pompe patients are the absence of cross reactive immunological material (CRIM) and an older age at start of therapy [12, 13]. In adults, antibody formation generally does not seem to interfere with ERT efficacy. However, some cases of adults with high antibody titers negatively affecting treatment outcomes have been reported [14–17]. Moreover, high antibody titers are associated with the occurrence of infusion-associated reactions (IARs) in adults [14]. Patients who developed symptoms and started ERT during childhood are an underrepresented group in previous studies on antibody formation during treatment with ERT. Here, we investigate the role of antibody formation in these patients, focusing on the antibody titers and their possible effects on clinical outcome and the occurrence of IARs during long-term treatment with ERT.

Results
Patient characteristics
The characteristics of the 22 patients included in this study are summarized in Table 1. Thirteen patients (58%) were male. Fifteen patients (68%) carried the common c.-32-13T > G (IVS1) disease-associated variant on one allele. The c.510C > T genetic modifier on the IVS1 allele, which is associated with lower α-glucosidase activity in fibroblasts and earlier symptom onset, was analysed in all IVS1 patients (n = 15) and found in seven patients (47%) [18]. Interestingly, five patients with the IVS1 variant had onset of symptoms within their first year of life, two of whom carried the genetic modifier. Three patients had hypertrophic cardiomyopathy at presentation (patient 3, 11 and 22; none of whom had the common IVS1 variant), which resolved after start of ERT in all three (data not shown). Age at start of ERT ranged from 1.1 to 16.4 years (median 10.3 years), the median duration of treatment was 12.4 years (range 2.2–19.6 years).

Initially, patients 7 and 8 received rhGAA from transgenic rabbit milk [19]. They were switched to infusions of rhGAA derived from Chinese hamster ovarian cells after approximately 3 years, initially receiving a dose of 20 mg/kg every other week and later 30 and 40 mg/kg every other week, respectively [20]. Two patients (patient 11 and 22) were treated with 40 mg/kg every week from start of treatment, while patient 13 switched from 20 mg/kg every other week to 40 mg/kg every other week during the course of the study because of clinical deterioration. All other patients (n = 17) were treated with the standard dose of 20 mg/kg every other week during the entire study. In patient 3, ERT was discontinued after 10 years of treatment because of end stage disease, this patient deceased 7.6 months after cessation of therapy.

Anti-rhGAA antibodies
Twenty patients (91%) developed anti-rhGAA IgG antibodies above the background titer of 1:250. In total, 12 of 152 samples (8%) showed a high titer (≥ 1:31,250) in at least one of the duplicate experiments. Based on the highest titer (peak titer) observed during the study period, patients were divided into three titer groups: two patients (9%) had low titers, 15 patients (68%) developed intermediate titers and five patients (23%) developed high titers, one of whom had a very high titer (1:156,250) at one time point (Fig. 1a). The mean antibody titer at group level showed a peak in antibody titer at three months of ERT, after which titers declined (Fig. 1b). Antibody titer courses of individual patients are shown in Fig. 2 (high titer group) and in Fig. 3 (low and intermediate titer groups). Titer courses varied between individual patients, most patients (18/22, 82%) developed their peak antibody titer within the first 12 months of ERT, after which the antibody titer declined and remained stable. Only one patient in the high titer group (patient 2) showed persistent high antibody titers (1:31,250) at all of the time points after the baseline measurement. Antibody titers declined in all the other patients, only patient 1 showed re-occurrence of high antibody titers (1:31,250) after 5 years of treatment. Two patients (patient 4 and 5) showed a high titer at only one time point and in only one of the duplicate experiments (Additional file 1: Figure S1). None of the patients receiving a higher than standard dose of alglucosidase alfa (i.e. > 20 mg/kg/2 weeks, patient 7, 8, 11, 13 and 22) showed high antibody titers. There was no correlation between age at start of ERT and peak antibody titer (Additional file 1: Figure S2).

Effect of GAA variant/activity on antibody formation
Of the five patients with a high peak titer, three were carrier of the common IVS1 variant on one allele and two carried other pathogenic variants (Table 1).
| Patient | Sex | Age symptom onset (y) | Disease-associated variant | Disease-associated variant 2 | Age start ERT (y) | ERT duration (y) | Wheelchair use | Ventilation use | IARs | Peak antibody titer |
|---------|-----|----------------------|---------------------------|-----------------------------|------------------|------------------|----------------|---------------|------|-------------------|
| 1       | F   | 0.2                  | c.2481 + 102_2646 + 31del | c.2102T > C                 | 1.7              | 5.9              | Yes            |               |      | 1:156,250         |
| 2<sup>1,2</sup> | M   | 11.8                 | c.-32-13T > G (IVS1)      | c.1441T > C                | 16.0             | 12.9             | No             |               |      | 1:31,250          |
| 3<sup>1,2</sup> | F   | 1.0                  | c.875A > G                | Unknown                     | 12.7             | 10.0             | Yes (6y)       | Invasive (6y) | Yes  | 1:31,250          |
| 4       | M   | 5.0                  | c.-32-13T > G (IVS1)      | c.525delT                   | 11.0             | 9.6              | No             |               |      | 1:31,250          |
| 5       | M   | 0.8                  | c.-32-13T > G (IVS1)      | c.525del                    | 9.8              | 7.9              | No             |               |      | 1:31,250          |
| 6<sup>1</sup> | M   | 2.5                  | c.-32-13T > G (IVS1)      | c.2331 + 2T > A            | 13.0             | 13.9             | No             |               |      | 1:6400            |
| 7<sup>1</sup> | F   | 10.0                 | c.875G > A + c.271G > A   | c.-32-3C > A               | 16.4             | 19.3             | Yes (16y)      | Non invasive (12y) | No  | 1:6250             |
| 8<sup>1</sup> | M   | 0.5                  | c.-32-13T > G (IVS1)      | c.525del                    | 11.9             | 19.3             | Yes (11y)      | No             |      | 1:6250             |
| 9<sup>1</sup> | F   | 6.5                  | c.-32-13T > G (IVS1)      | c.525del                    | 12.7             | 13.9             | No             |               |      | 1:6250             |
| 10      | M   | 8.9                  | c.-32-13T > G (IVS1)      | c.525del                    | 10.5             | 6.4              | No             |               |      | 1:6250             |
| 11<sup>1,2</sup> | M   | 1.0                  | c.379_380del              | c.875A > G                 | 3.4              | 3.4              | No             |               |      | 1:6250             |
| 12<sup>1,2</sup> | M   | 2.0                  | c.-32-13T > G (IVS1)      | c.525del                    | 13.1             | 14.3             | Yes            |               |      | 1:1250             |
| 13<sup>1</sup> | M   | 2.7                  | c.1634C > T               | c.2481 + 102_2646 + 31del  | 6.0              | 13.9             | No             |               |      | 1:1250             |
| 14<sup>1</sup> | M   | 1.0                  | c.-32-13T > G (IVS1)      | c.525del                    | 15.2             | 13.9             | Non invasive (12y) | No  | 1:1250         |
| 15<sup>1</sup> | F   | 0.8                  | c.-32-13T > G (IVS1)      | c.923A > C                 | 8.9              | 13.9             | No             |               |      | 1:1250             |
| 16<sup>1,2</sup> | M   | 0.8                  | c.-32-13T > G (IVS1)      | c.2135T > C                | 2.9              | 13.7             | Yes            |               |      | 1:1250             |
| 17      | F   | 6.0                  | c.1829C > T               | c.1912G > T                | 10.1             | 12.8             | Yes (9y)       | Non invasive (8y) | No  | 1:1250             |
| 18<sup>1</sup> | M   | 13.0                 | c.-32-13T > G (IVS1)      | c.1933G > A                | 14.3             | 11.9             | No             |               |      | 1:1250             |
| 19<sup>1</sup> | F   | 0.8                  | c.-32-13T > G (IVS1)      | c.2135T > C                | 1.1              | 9.9              | No             |               |      | 1:1250             |
| 20      | F   | 5.0                  | c.-32-13T > G (IVS1)      | c.2331 + 2T > A            | 8.5              | 8.5              | No             |               |      | 1:1250             |
| 21<sup>1</sup> | F   | 1.0                  | c.-32-13T > G (IVS1)      | c.525del                    | 1.9              | 3.9              | No             |               |      | 1:250              |
| 22<sup>1,2</sup> | M   | 1.3                  | c.1115A > T               | c.1115A > T                | 1.4              | 2.2              | No             |               |      | 1:250              |

Overall

| Male | N = 13 (50%) | | | | | | | | 10.3 (1.1–16.4) | 12.4 (2.2–19.6) | N = 4 (18%) | N = 4 (18%) | IARs N = 4 (18%) | High peak titer N = 5 (23%) |

**Bold** = high peak titer patients, **italics** = intermediate peak titer patients, **bold italics** = low peak titer patients

Data are median (range) unless indicated otherwise. § IVS1 patients with c.510C > T genetic modifier; ¥ patients with hypertrophic cardiomyopathy at presentation; † patient deceased; * siblings; ‡ siblings; a patients who participated in van der Ploeg et al. 2010 (start ERT in 2006); b patients who participated in Capelle et al. 2010 (start ERT in 2005); c patients who initially started on recombinant human alpha-glucosidase from rabbit milk in 1999 and were switched to a higher dose of alglucosidase alfa (Winkel 2004); ‡ patients treated with a dose of 40 mg/kg every week; ‡ patients who started ERT in 2004/2005 as part of an expanded access program; * patients who were switched to a dose of 40 mg/kg every 2 weeks after 13.3 years of treatment
Of the three patients with a high titer at more than one time point, one was carrier of the IVS1 variant (patient 2), one carried a potentially mild variant (c.875A>G) and an unknown variant (patient 3) and one (patient 1) was carrier of one severe variant (c.2481+102_2646+31del) and one potentially less severe variant (c.2102T>C) [21]. The c.875A>G variant is a potentially mild variant leading to an amino acid substitution with no effect on splicing. The c.2481+102_2646+31del variant on the other hand, is a very severe variant, leading to an in frame skip of exon 18 and as a consequence an abnormal GAA protein (www.pompevariantdatabase.nl) [21], whereas the c.2102T>C variant was predicted to be a potentially less severe, missense variant (p.Leu701Gln, own prediction). The distribution of peak antibody titers did not differ between patients with/without the IVS1 variant (Fig. 4). The IVS1 variant affects pre-mRNA splicing and induces full or partial skipping of exon 2 of GAA as well as utilization of a pseudo exon in intron 1. It allows a low level of (10–15%) of leaky wild type splicing [18]. Of the seven patients with the c.510C>T genetic modifier on the IVS1 allele, one patient had a low peak titer, five patients had an intermediate peak titer and one patient developed a high peak titer [18]. The patient with the highest titer (1:156,250) was carrier of one severe variant and one potentially less severe variant. We did not find a significant correlation between residual (endogenous) α-glucosidase activity in fibroblasts and peak antibody titer (Additional file 1: Table S1 and Figure S3).

Infusion associated reactions

Four patients (18%) developed IARs during treatment; the distribution of the occurrence of IARs between the titer groups is shown in Fig. 5a. In most patients, the first IAR occurred within the first year of treatment (median onset of IARs after start of ERT 0.21 years, range 0.11–1.15 years). Infusion associated reactions occurred in 59 infusions out of a total of approximately 6200 infusions administered over the years. All IARs occurred during the infusion or within 2 h after completion of the infusion. Types and frequencies of IAR symptoms are summarized in Additional file 1: Table S2. Most common symptoms were nausea, dizziness and exanthema. In general, IAR symptoms were mild and 58 of 59 of infusions (98%) in which IARs occurred could be completed on the same day, after a short interruption of the infusion (n=24) or an interruption of the infusion plus administration of antihistamines (n=15). In 13/15 (87%) of the infusions in which antihistamines had to be administered it concerned patients from the high titer group (n=11 in patient 1 and n=2 in patient 3). In 20 infusions with IARs, no specific action to complete the infusion had to be undertaken. Only one infusion had to be discontinued, due to more severe symptoms (generalized urticaria, coughing and sweating), which did not completely resolve after administration of antihistamines. Next infusions in this patient were given with premedication (clemastine).
Fig. 2 Clinical parameters, anti-recombinant human acid α-glucosidase (anti-rhGAA) antibody titers, neutralizing effects and infusion associated reactions (IARs) for five patients with a high or very high peak antibody titer. Each graph represents an individual patient. For each patient, anti-rhGAA antibody titers are shown on the left Y-axis, the effect of antibody titers on intracellular rhGAA activity (%) is shown on the right Y-axis. The occurrence of IARs is displayed (exclamation marks). Clinical outcome parameters, the Medical Research Council (MRC) sum score (expressed as a percentage of maximal muscle strength), Forced Vital Capacity (FVC) in upright position (expressed as a percentage of predicted normal values) and Quick Motor Function Test (QMFT) sum score (expressed as a percentage of the maximal score), are shown on the right Y-axis.
and adjusted infusion rates and could be fully completed, although localized urticaria (on arms/legs) occurred in two more infusions in the two months following the first IAR. The patient with the persistent high antibody titer (patient 2) did not develop any IARs. The patient with the highest peak titer (patient 1) showed the largest number of infusions with IARs (n = 28). Overall, the correlation between the number of IARs and the peak antibody titer was not statistically significant (Spearman $\rho = 0.234$, $p = 0.295$; Fig. 5b). No patients had to discontinue ERT permanently because of (severe) IARs and no patients experienced IARs at the end of the study.

Neutralizing effects of anti-rhGAA antibodies
Our previous studies in classic infantile and adult Pompe patients showed that the threshold titer at which neutralizing effects may be observed is 1:31,250 [12, 14]. For all five patients in the high peak titer group, at least one of the high titer samples was analyzed for neutralizing effects in vitro. In total, seven of the twelve samples with a titer of $\geq 1:31,250$ were analyzed: six samples with an antibody titer of 1:31,250 and one sample with a titer of 1:156,250. Intracellular rhGAA activity in the analyzed samples, which reflects the combined effects of antibodies on cellular uptake and enzyme activity, is shown in Fig. 2. Inhibited enzyme activity of 58% in cells was observed in only one sample of patient 3 at time point t = 6 months (antibody titer 1:31,250). In the other samples, intracellular rhGAA activity was not inhibited, not even in the sample with the highest titer. None of the analyzed samples showed inhibited enzyme activity in medium (data not shown).

Effect of antibodies on clinical outcome
Clinical course (MRC sum score, QMFT sum score, FVC in upright position) of the five patients in the high peak titer group was analyzed on an individual basis (Fig. 2). Patient 2, 4 and 10 showed a stable course of clinical outcome measures throughout the study. Patient 3 was only 1 year old when ERT was started, therefore assessment of the MRC, QMFT and FVC could not be performed during the first years of treatment. The motor domain of the Bayley Scales of Infant Development-II (BSID-II), which is a tool for developmental assessment in the first 2 years of life, showed a delayed motor development at start of ERT (BSID-II SD score $< -3.0$) [22]. During the first 2 years of treatment, the BSID-II improved to SD scores between $-1.7$ and $-0.6$, which are age-equivalent scores, reflecting normal development (Additional file 1: Table S3). Quick Motor Function Test sum score, MRC sum score and FVC showed a stable or improving course during the study period. In addition, we did not observe a decline in any of the outcome measures when high antibody titers reoccurred after 5 years of treatment. In conclusion, none of the patients showed clear evidence of interference of anti-rhGAA antibodies with ERT efficacy.

Discussion
In this study, we investigated antibody formation and its possible effects on clinical outcome and the occurrence of IARs during long-term treatment with ERT in childhood onset Pompe disease patients, who also started ERT during childhood. The majority of patients developed anti-rhGAA antibodies above background level, but high peak titers were found in only 23% of patients and a high persistent titer in only one patient. Moreover, only 8% of all samples showed a high titer. We did not observe clear effects of high antibody titers on clinical outcomes, indicating that antibodies do not play a major role in ERT efficacy in childhood onset Pompe disease.

The proportion of patients with a (very) high peak titer in our study is comparable to what we previously reported in adult patients (23% vs. 22%) [14]. We found high sustained antibody titers in only one patient (with short follow up duration), which is also comparable to adults, but in contrast to what is reported in classic infantile Pompe disease patients, especially in CRIM negative patients [13, 22]. We postulated that lower endogenous $\alpha$-glucosidase activity may lead to higher antibody titers, which was previously hypothesized in adults too [14]. However, we did not find a significant correlation between endogenous $\alpha$-glucosidase activity and peak titer, although this might (partly) be due to the small number of patients. At an individual level, patients with high peak antibody titers did not have remarkable low $\alpha$-glucosidase activity compared to patients from the
Fig. 3  (See legend on previous page.)
intermediate and low titer groups. Moreover, the patient with the lowest α-glucosidase activity had low peak anti-
body titers.

Enzyme replacement therapy efficacy was not influ-
enced by high antibody titers in childhood onset
patients, not even in the patient with a very high peak
titer (1:156,250). However, subtle decline in clinical out-
comes may be overlooked, since four of five patients in
the high titer group reached maximum scores (100%)
on different outcomes at multiple time points (ceiling
effect). The patient with a persistent high antibody titer
did not show clinical decline, although follow up dura-
tion in this patient was only 18 months. Our findings
are in contrast to the findings in classic infantile Pompe
disease, in which particularly CRIM negative patients
are at risk of developing high-sustained antibody titers,
which counteract the positive effects of ERT [12, 13].
However, high-sustained antibody titers with negative
effects on treatment outcome have also been reported in
CRIM positive patients and CRIM status alone does not
predict the height or duration of the antibody response
[12, 23–25]. Moreover, also adult Pompe patients can
develop antibodies against rhGAA that interfere with
treatment efficacy [15, 16]. Other factors that have been
described to influence antibody formation in classic
infantile Pompe patients are dosing of rhGAA and age of
treatment initiation [12, 22, 26, 27]. Contrary to what was
previously reported, we did not observe development of

![Fig. 4 Peak anti-recombinant human acid α-glucosidase (anti-rhGAA) antibody titers in relation to genotype. Pie charts of the distribution of antibody titer groups across patients with (n=15) and without (n=7) the c.32-13 T>G (IVS1) variant](image)

![Fig. 5 Infusion associated reactions (IARs). a The number of patients with and without infusion associated reactions (IARs) across the three anti-recombinant human acid α-glucosidase (anti-rhGAA) antibody titer groups. b Correlation between the number of IARs and peak anti-rhGAA antibody titers (Spearman ρ = 0.234, p = 0.295)](image)
high antibody titers in any of the patients treated with a higher dose (>20 mg/kg/week) [22, 26]. This applied for patients treated with a higher dose (40 mg/kg/week) from start of treatment, as well as for patients who later switched to a higher dose of rhGAA. In addition, we did not find a relation between age at start of ERT and (peak) antibody titer. However, as age at start of ERT was considerably higher in our patients (all over 1 year of age) compared to the classic infantile patients in previous studies, which reported that patients who started ERT within the first two months of life developed lower titers, the comparison of these patient groups might not be valid [12, 27].

Most patients reached their peak antibody titer within the first year of treatment. This is similar to what we found in our adult cohort and is in line with the reported decrease of antibodies and absence of neutralizing antibodies after long-term exposure to rhGAA [14, 17]. Two of the five patients with a high peak titer showed a high titer (of 1:31,250) at only one time point and only in one of the two experiments, the other experiment showed a titer of 1:6250 (intermediate titer). Differences between the two experiments are caused by the five-fold dilution series used to determine titers, which can result in a titer closest to either 1:6250 or 1:31,250 and thus indicates that the actual titer lies between 1:6250 and 1:31,250. Importantly, these patients showed a stable disease course and never experienced IARs.

Only one patient showed inhibited intracellular rhGAA activity, in one sample with an antibody titer of 1:31,500 at 3 months of treatment. Although this patient was already diagnosed at an early age (symptom onset at the age of 1 year; hypertrophic cardiomyopathy), unfortunately ERT could not be started until the age of 12 years, when ERT was registered as treatment for Pompe disease. Consequently, this patient was already very severely affected (completely wheelchair dependent and invasively ventilated) at start of treatment. Because of further deterioration despite ERT, ERT was discontinued at the age of 22. The patient deceased almost eight months thereafter, at the age of 23. The assessment of clinical outcome measures was complicated by the fact that only manual muscle testing (MRC) could be performed at limited time points. However, the hypertrophic cardiomyopathy resolved after start of ERT and antibody titers declined to intermediate titers after 12 months of treatment. A potential neutralizing effect was only found at one time point, 1 year before clinical deterioration occurred. It can not be ruled out that the neutralizing antibodies contributed to the observed clinical deterioration to some extent in this patient. The other patients with high antibody titers did not show inhibited intracellular GAA activity. Based on the data we present in this study, we postulate that neutralizing antibodies do not play a major role in the efficacy of ERT in childhood onset Pompe disease patients.

In four patients (18%) IARs occurred during treatment, which is a similar percentage to what has been reported in adult patients [14, 28–31]. Eighty-nine percent of the IARs could be managed by a short interruption of the infusion, slowing the infusion rate and/or administration of antihistamines. None of the patients had to discontinue ERT permanently due to IARs. Contrary to what we previously reported in adult patients, we did not find a statistically significant correlation between the peak antibody titer and number of IARs in our patients [14]. This might be due to the small number of patients with IARs, since it is remarkable that the patient with the highest peak antibody titer showed the largest number of IARs and experienced more severe IARs. Moreover, the majority of the total number of IARs (86%) was observed in patients in the high titer group. Thus, there may be an association between high antibody titers and the occurrence of IARs in children as well.

With regard to a possible association between genotype and antibody titers, we did not find any clear associations. However, this could be due to the small number of patients and broad variation of different pathogenic variants among these patients. We found that the patient with the highest antibody titer was not a carrier of the IVS1 variant, whereas most other patients were.

Although high sustained antibody titers do not seem to play a major role in late onset Pompe disease, personalized immunogenicity risk assessment (PIMA) could be a helpful tool to identify patients who are at risk for developing high antibody titers [32]. With PIMA, the risk of developing antibodies (in CRIM positive Pompe disease patients) is predicted by using information about a patient’s native GAA gene and their HLA DR haplotype. This tool is developed using data of infantile onset Pompe disease patients and it predicts the anti-drug antibody status accurately in 64% of patients. To use this tool more broadly, it should first be validated for use in late-onset Pompe disease patients and the accuracy of the model should be refined further. If the tool proofs to be valid in late-onset Pompe disease too, it could be used to differentiate high-risk from low-risk patients and identify patients in whom antibody titers should be monitored more closely.

The most important limitation of our study is the small patient population, inherent to rare diseases. Additionally, we only found potential neutralizing antibodies in one sample of a severely affected patient, with limited availability of clinical data. Therefore, the effect of neutralizing antibodies on clinical outcome remains somewhat uncertain. To draw more robust conclusions, future...
studies should aim to increase patient numbers, for which international collaboration is needed.

**Conclusions**

We conclude that the majority of patients with childhood onset Pompe disease do not develop high antibody titers. High antibody titers do not seem to affect clinical outcome, but may be associated with the occurrence of IARs. Although we did not observe clinical deterioration in our patients with a high peak antibody titer, interference of high antibody titers (with neutralizing effects) with treatment efficacy has previously been reported in late-onset Pompe disease patients [15, 16]. We therefore suggest that antibody titers should be determined in case of (unexpected) clinical deterioration, especially when this decline is accompanied by IARs. If high antibody titers with neutralizing effects are found and judged to be the causative factor for the observed clinical deterioration, immunomodulation, which is used to counteract antibody formation in classic infantile Pompe disease patients, could be considered in late-onset patients as well [22, 23, 25, 33].

**Methods**

**Population and study design**

We included patients with childhood onset Pompe disease in whom ERT had been started before the age of 18 years. The diagnosis was confirmed by diagnostic enzyme analysis in leukocytes and/or fibroblasts and by mutation analysis. Patients with classic infantile Pompe disease were excluded. Classic infantile Pompe disease was defined as symptoms of (a) muscle weakness within 6 months after birth, (b) hypertrophic cardiomyopathy, (c) less than 1% α-glucosidase activity in fibroblasts, and (d) severe mutations in both GAA alleles. The study was conducted at the Center for Lysosomal and Metabolic Diseases, Erasmus MC University Medical Center in Rotterdam. This is the single reference center for Pompe patients in the Netherlands. Since also patients from outside the Netherlands have been treated and followed in our center as part of several clinical studies, this study includes 16 patients from the Netherlands, two from Belgium, two from Germany, and one patient from the UK and one from the USA [19, 29, 34].

Clinical assessments were performed every 3–6 months by specialized physical therapists and clinicians. Data were collected prospectively from June 1999 to January 2019. Before market approval in 2006, ERT was given as part of trials [19, 29, 34]. Infusions were given in standardized infusion schedules (Additional file 1: Table S4). In case of IARs, infusion schedules were adapted at the discretion of the treating physician. All patients and/or their parents provided written informed consent.

**Antibodies and neutralizing effects**

For all patients, anti-rhGAA IgG antibody titers were determined at standard time points: before start of ERT (t = 0) and during ERT at 3, 6 and 12 months and at 3, 5, 7, 11, 15 and 19 years (if applicable). In addition, the sample drawn at the patient’s last visit was analyzed. For two patients, no samples before start of ERT were available. If high antibody titers were found, additional samples at intermediate time points were tested. In total, 152 samples were analyzed. Blood samples were drawn before the infusion or, for patients receiving treatment at home, on a day when patients did not receive ERT. If no sample was available at the before mentioned standard time point, the sample closest to the time point was used.

Antibody titers were determined in plasma or serum using ELISA with fivefold dilution series, as previously described [12, 14]. Experiments were performed in duplicate and repeated at least two times for high titers. The highest titer measured per sample was reported and used for analysis. On each plate, a positive control (i.e. rabbit antisera) and a negative control (serum from a mix of healthy persons) were included.

For five patients participating in an open-label study, ELISA results obtained during this study are reported for time point 3 months (patient 15), 3 and 6 months (patient 9, 13 and 14) and 3, 6 and 12 months (patient 6) [34]. For patient 2, antibody titers obtained during the randomized controlled Late-Onset Treatment Study (LOTS) are also reported [29]. Antibody titers cutoffs were based on data derived from classic infantile and adult cases: no-low titer (< 1:1250), intermediate titer (1:1250 to < 1:31,250) and high titers (≥ 1:31,250) [12, 14].

The effects of antibodies on the uptake of rhGAA (neutralizing effects) were determined by adding an amount equivalent to 200 nmol 4-Methylumbelliferyl-α-D-glucopyranoside monohydrate (MUGlc)/h α-glucosidase alfa per 200 μL medium and 20 μL of the patients’ serum to the medium of α-glucosidase deficient fibroblasts, followed by measurement of α-glucosidase activity in cells and medium, as described before [12, 14]. The experiment was performed in duplicate and repeated if needed. Fibroblasts and medium were harvested after 24 h. Alpha-glucosidase activity was expressed as a percentage of the activity present in medium containing fetal calf serum and measured 24 h after addition of rhGAA to the medium. We defined a neutralizing effect as a diminished enzyme activity both intracellularly and in medium. A potential neutralizing effect was defined as a diminished enzyme activity intracellular only; this can be evidence of neutralizing antibodies or of a decreased cellular uptake of the enzyme.
Infusion-associated reactions and clinical outcome measures
If an IAR occurred during or following an rhGAA infusion, IAR symptoms and treatment were recorded. Only IARs judged to have a possible, probable or definite relationship with the infusion were included in this study.

Skeletal muscle strength was measured by manual muscle testing using the Medical Research Council (MRC) grading scale (range 0–5) [35]. Muscle groups tested comprised the neck flexors, neck extensors, shoulder abductors, elbow flexors, elbow extensors, wrist extensors, hip flexors, hip extensors, hip abductors, hip adductors, knee flexors, knee extensors, foot dorsal flexors, and foot plantar flexors.

Muscle function was assessed using the Quick Motor Function Test (QMFT), which evaluates 16 motor skills that are specifically challenging for patients with Pompe disease [36]. For the MRC and QMFT, sum scores were derived as described previously [37]. If values for two or more items were missing, no sum score was calculated.

 Forced vital capacity (FVC) was measured in upright and supine positions according to ATS/ERS standards [38]. Results were expressed as a percentage of the predicted normal values [39].

Statistical analysis
We used descriptive statistics (including median and range) to summarize demographic data. For correlations, Spearman’s rho test was used. Because of limited statistical power due to small group sizes, effects of antibodies on clinical outcome measures were described on an individual basis. Statistical analyses were performed using SPSS for Windows (version 25; SPSS Inc, Chicago, IL) and GraphPad Prism (version 5.01 for Windows, GraphPad Software, La Jolla California USA). A p-value of < 0.05 (two-sided) was considered statistically significant.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s13023-022-02175-2.

Acknowledgements
Several of the authors of this publication are members of the European Reference Networks for Hereditary Metabolic Disorders (Metab-ERN) and Rare Neur muscular Diseases (EURO-NMD) and/or of the Netherlands Neuromuscular Center (NL-NMD).

Authors’ contributions
Conceptualization: HvK, MHW, JvdH, PV, WP, AvdP, NvdB; Data curation: HvK, ID; Formal Analysis: HvK, NvdB; Funding acquisition: JvdH, AvdP, NvdB; Investigation: HvK, ID, MHW, JvdH, AvdP, NvdB; Methodology: HvK, MHW, EJ, WP; Project administration: HvK, ID, NvdB; Resources: MHW, EJ, PV, WP, AvP; Supervision: MHW, JvdH, PV, AvdP, NvdB; Validation: HvK, MHW; Visualization: HvK, NvdB; Writing — original draft: HvK, ID, NvdB; Writing — review & editing: HvK, ID, MHW, EJ, JvdH, PV, WP, AvdP, NvdB. All authors read and approved the final manuscript.

Funding
This study was funded by ZonMW—the Netherlands Organization for Health Research and Development [Grant No. 09150161910230 (Ven) to NvdB]; Sophia Children’s Hospital Foundation (SSWO) [Project No. S17-32]; Metakids [Project No. 2016-063], Ministry of Economic Affairs under TRI-Allowance under the TRI-program Life Sciences & Health [Project No. LSHM16008]. This study was also supported in part by Sanofi-Genzyme. Sanofi-Genzyme did not have any influence on the content or design of the study and the drafting and content of the manuscript nor did Sanofi-Genzyme cover the costs of the study drug. NvdB received a post-doctoral fellowship from the Prinses Beatrix Spierfonds (WF16-03). The authors confirm independence from the sponsors; the content of the article has not been influenced by the sponsors.

Availability of data and materials
The corresponding author takes full responsibility for the data, has full access to all data and has the right to publish all data apart from any sponsor. Anonymized data will be shared by request from any qualified investigator for the sole purpose of replicating procedures and results presented in the article, and as long as data transfer is in agreement with EU legislation on the general data protection regulation.

Declarations
Ethics approval and consent to participate
This study was approved by the medical ethical committee of the Erasmus MC.

Consent for publication
We received informed consent forms from all participants and/or their caregivers in this study; all forms are on file and available in case of request. All individual patient data was de-identified.

Competing interests
J.M.P. van den Hout, A.T. van der Ploeg, and N.A.M.E. van der Beek, received funding for research, clinical trials and as advisor from various industries working on enzyme-replacement therapy or next-generation therapies in the field of Pompe disease, other lysosomal storage diseases or neuromuscular disorders, under agreements with Erasmus MC University Medical Center and the relevant industry. M. Hoogeveen-Westerveld and E.H. Jacobs performed diagnostic assays for Spark Therapeutics. H.A. van Kooten, I.A.M. Ditters, P.A. van Doorn and W.W.M. Pijnappel declare no potential conflict of interest.

Author details
1 Department of Neurology, Center for Lysosomal and Metabolic Diseases, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands. 2 Department of Pediatrics, Center for Lysosomal and Metabolic Diseases, Erasmus MC - Sophia Children’s Hospital, University Medical Center Rotterdam, Rotterdam, The Netherlands. 3 Department of Pediatrics, Department of Clinical Genetics, Center for Lysosomal and Metabolic Diseases, Erasmus MC, University Medical Center, Rotterdam, The Netherlands. 4 Department of Neurology, Erasmus University Medical Center, Mailbox 2040, 3000 CA Rotterdam, the Netherlands.
References

1. van der Ploeg AT, Reuser AJ. Pompe’s disease. Lancet. 2008;372(9646):1342–53.

2. van den Hout HM, Hop W, van Diggelen OP, Smeitink JA, Smit GP, Poll-The BT, et al. The natural course of infantile Pompe’s disease: 20 original cases compared with 133 cases from the literature. Pediatrics. 2003;112(2):332–40.

3. van Capelle CI, van der Meijden JC, van den Hout JM, Jaeken J, Baethmann M, Voit T, et al. Childhood Pompe disease: clinical spectrum and genotype in 31 patients. Orphanet J Rare Dis. 2016;11(1):65.

4. van der Beek NA, Hagemans ML, van der Ploeg AT, Reuser AJ, van Doorn PA. Pompe disease (glycogen storage disease type II): clinical features and enzyme replacement therapy. Acta Neurol Belg. 2006;106(2):82–9.

5. Kuperus E, Kruisshaar ME, Wens SC, de Vries JM, Favejee MM, van der Meijden JC, et al. Long-term benefit of enzyme replacement therapy in Pompe disease: A 5-year prospective study. Neurology. 2017;89(23):2366–73.

6. Van den Hout JM, Kamphoven JH, Winkel LP, Arts WF, De Klerk JB, Loonen MC, et al. Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk. Pediatrics. 2004;113(5):e448–57.

7. Güngör D, Kruisshaar ME, Plug I, D’Agostino RB, Hagemans ML, van Doorn PA, et al. Impact of enzyme replacement therapy on survival in adults with Pompe disease: results from a prospective international observational study. Orphanet J Rare Dis. 2013;8:49.

8. Güngör D, Kruisshaar ME, Plug I, Rozopoulos D, Kanters TA, Wens SC, et al. Quality of life and participation in daily life of adults with Pompe disease receiving enzyme replacement therapy. 10 years of international follow-up. J Inherit Metab Dis. 2016;39(2):253–60.

9. Kishnani PS, Corzo D, Nicollino M, Byrne B, Mandel H, Hwu WL, et al. Recombinant human acid (alpha)-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology. 2007;68(2):99–109.

10. Schoser B, Stewart A, Kanters S, Hamed A, Jansen J, Chan K, et al. Survival and long-term outcomes in late-onset Pompe disease following alglucosidase alfa treatment: a systematic review and meta-analysis. J Neurol. 2016;263(4):621–30.

11. Broomfield A, Jones SA, Hughes SM, Bigger BW. The impact of antibodies in late-onset Pompe disease: a case series and long-term outcomes in late-onset Pompe disease following alglucosidase alfa treatment in lysosomal storage disorders. J Inherit Metab Dis. 2016;39(4):499–512.

12. van Gelder CM, Hoogeveen-Westerveld M, Kroos MA, Plug I, van der Ploeg AT, Reuser AJ. Enzyme therapy and immune response in relation to CRIM status: the Dutch experience in classic infantile Pompe disease. J Inherit Metab Dis. 2013;36(2):305–14.

13. Kishnani PS, Goldenberg PC, DeArmsy SL, Heller J, Benjamin D, Young S, et al. Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants. Mol Genet Metab. 2010;99(1):26–33.

14. de Vries JM, Kuperus E, Hoogeveen-Westerveld M, Kroos MA, Wens SC, Stok M, et al. Pompe disease in adulthood: effects of antibody formation on enzyme replacement therapy. Genet Med. 2017;19(1):90–7.

15. de Vries JM, van der Beek NA, Kroos MA, Ozkan L, van Doorn PA, Richards SM, et al. High antibody titer in an adult with Pompe disease affects treatment with alglucosidase alfa. Mol Genet Metab. 2010;101(4):338–45.

16. Patel TT, Banugaria SG, Case LEW, Wenninger S, Schoser B, Kishnani PS. The impact of antibodies in late-onset Pompe disease: a case series and literature review. Mol Genet Metab. 2012;106(3):301–9.

17. Masat E, Lafont P, De Antonio M, Coreg G, Pernicone B, Tauragiu N, et al. Long-term exposure to Myozyme results in a decrease of anti-drug antibodies in late-onset Pompe disease patients. Sci Rep. 2016;6:36182.

18. Bergsma AJ, In’t Groen SLM, van den Dorel JJA, van den Hout H, van der Beek N, Schoser B, et al. A genetic modifier of symptom onset in Pompe disease. EBioMedicine. 2019;43:533–61.

19. Winkel LP, Van den Hout JM, Kamphoven JH, Disselbroe JP, Remmerswaal M, Arts WF, et al. Enzyme replacement therapy in late-onset Pompe’s disease: a three-year follow-up. Ann Neurol. 2004;55(4):495–502.

20. van Capelle CI, Winkel LP, Hagemans ML, Shapira SK, Arts WF, van Doorn PA, et al. Eight years experience with enzyme replacement therapy in two children and one adult with Pompe disease. Neuromuscul Disord. 2008;18(6):447–52.

21. Niño MY, In’t Groen SLM, Bergsma AJ, van der Beek N, Kroos M, Hoogeveen-Westerveld M, et al. Extension of the Pompe mutation database by linking disease-associated variants to clinical severity. Hum Mutat. 2019;40(1):1954–67.

22. Poelman E, van den Dorel JJA, Hoogeveen-Westerveld M, van den Hout JMP, van der Giessen LJ, van der Beek N, et al. Effects of higher and more frequent dosing of alglucosidase alfa and immunomodulation on long-term clinical outcome of classic infantile Pompe patients. J Inherit Metab Dis. 2020;43(6):1243–53.

23. Banugaria SG, Prater SN, Ng YK, Kobori JA, Finkel RS, Ladda RL, et al. The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: lessons learned from infantile Pompe disease. Genet Med. 2011;13(8):729–36.

24. Desai AK, Kazi ZB, Bali DS, Kishnani PS. Characterization of immune response in Cross-Reactive Immunological Material (CRIM)-positive infantile Pompe disease patients treated with enzyme replacement therapy. Mol Genet Metab Rep. 2019;20:100475.

25. Poelman E, Hoogeveen-Westerveld M, van den Hout JMP, Bredius RGM, Lankester AC, Griessen GA, et al. Effects of immunomodulation in classic infantile Pompe disease patients with high antibody titers. Orphanet J Rare Dis. 2019;14(1):71.

26. Nayak S, Doerfler PA, Porvasnik SL, Cloutier DD, Khanna R, Valenzano KJ, et al. Immune responses and hypercoagulation in ERT for Pompe disease are mutation and rhGAA dose dependent. PLoS ONE. 2014;9(6):e98356.

27. van Gelder CM, Poelman E, Plug I, Hoogeveen-Westerveld M, van der Beek N, Reuser AJ, et al. Effects of a higher dose of alglucosidase alfa on ventilator-free survival and motor outcome in classic infantile Pompe disease: an open-label single-center study. J Inherit Metab Dis. 2016;39(3):383–90.

28. Regnery C, Konbrum C, Hanisch F, Velihaber S, Strigl-Pill N, Grunert B, et al. 36 months observational clinical study of 38 adult Pompe disease patients under alglucosidase alfa enzyme replacement therapy. J Inherit Metab Dis. 2012;35(5):837–45.

29. van der Ploeg AT, Clemens PR, Corzo D, Escolar DM, Florence J, Groen-Egel JJ, et al. A randomized study of alglucosidase alfa in late-onset Pompe disease. N Engl J Med. 2010;362(15):1396–406.

30. Fernández-Simón E, Carrasco-Rozas A, Gallardo E, González-Quereda L, Alonso-Pérez J, Belmonte I, et al. Study of the effect of anti-rhGAA antibodies at low and intermediate titers in late onset Pompe patients treated with ERT. Mol Genet Metab. 2019;128(1–2):129–36.

31. Case LE, Bjartmar C, Morgan C, Casey R, Charrow J, Clancy JP, et al. Safety and efficacy of alternative alglucosidase alfa regimens in Pompe disease. Neuromuscul Disord. 2015;25(4):321–32.

32. De Groot AS, Desai AK, Leelas S, Miah SMS, Terry FE, Khan S, et al. Immune tolerance-adjusted personalized immunogenicity prediction for Pompe disease. Front Immunol. 2021;12:636731.

33. Desai AK, Baloh CH, Slesawman J, Rosenberg AS, Kishnani PS. Benefits of prophylactic short-course immune tolerance induction in patients with infantile Pompe disease: demonstration of long-term safety and efficacy in an expanded cohort. Front Immunol. 2020;11:1727.

34. van Capelle CI, van der Beek NA, Hagemans ML, Arts WF, van Doorn PA, Lee P, et al. Effect of enzyme therapy in juvenile patients with Pompe disease: a three-year open-label study. Neuromuscul Disord. 2010;20(11):1954–67.

35. Medical Research Council. Aids to the examination of the peripheral nervous system, Memorandum No. 45. London: Her Majesty’s Stationary Office; 1978.

36. van Capelle CI, van der Beek NA, de Vries JM, van Doorn PA, Duivenvoorden HJ, Leshter RT, et al. The quick motor function test: a new tool to rate clinical severity and motor function in Pompe patients. J Inherit Metab Dis. 2012;35(2):317–23.

37. de Vries JM, van der Beek NA, Hop WC, Karsten FP, Wokke JH, de Visser M, et al. Effect of enzyme therapy and prognostic factors in 69 adults with Pompe disease: an open-label single-center study. Orphanet J Rare Dis. 2012;7:73.

38. van Kooten
39. Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH, et al. Multi-ethnic reference values for spirometry for the 3–95-yr age range: the global lung function 2012 equations. Eur Respir J. 2012;40(6):1324–43.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.